Christine Cheung

Dr. Christine Cheung

Lee Kong Chian School of Medicine, Nanyang Technological University Singapore
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2012 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
CCChristine Cheung
Christine Cheung
ABAndreia Sofia Bernardo
Andreia Sofia Bernardo
MTMatthew W B Trotter
Matthew W B Trotter
RPRoger A Pedersen
Roger A Pedersen
SSSanjay Sinha
Sanjay Sinha
Vascular smooth muscle cells have multiple embryological origins. Cheung et al. present a chemically defined protocol for differentiating human pluripotent stem cells into vascular smooth muscle subtypes arising from neuroectoderm, lateral plate mesoderm and paraxial mesoderm. Heterogeneity of embryological origins is a hallmark of vascular smooth muscle cells (SMCs) and may influence the development of vascular disease. Differentiation of human pluripotent stem cells (hPSCs) into developmental origin–specific SMC subtypes remains elusive. Here we describe a chemically defined protocol in which hPSCs were initially induced to form neuroectoderm, lateral plate mesoderm or paraxial mesoderm. These intermediate populations were further differentiated toward SMCs (>80% MYH11+ and ACTA2+), which displayed contractile ability in response to vasoconstrictors and invested perivascular regions in vivo. Derived SMC subtypes recapitulated the unique proliferative and secretory responses to cytokines previously documented in studies using aortic SMCs of distinct origins. Notably, this system predicted increased extracellular matrix degradation by SMCs derived from lateral plate mesoderm, which was confirmed using rat aortic SMCs from corresponding origins. This differentiation approach will have broad applications in modeling origin-dependent disease susceptibility and in developing bioengineered vascular grafts for regenerative medicine.

19 October 2023 in Advanced Materials
Verified
Journal Article
Closed access
YSYufeng Shou
Yufeng Shou
ZLZhicheng Le
Zhicheng Le
HCHong Sheng Cheng
Hong Sheng Cheng
QLQimin Liu
Qimin Liu
YNYi Zhen Ng
Yi Zhen Ng
ATAndy Tay
Andy Tay

23 March 2021 in eLife
Verified
Journal Article
Open access
FCFlorence Wj Chioh
Florence Wj Chioh
SFSiew-Wai Fong
Siew-Wai Fong
BYBarnaby E Young
Barnaby E Young
KWKan-Xing Wu
Kan-Xing Wu
ASAnthony Siau
Anthony Siau
CCChristine Cheung
Christine Cheung
Numerous reports of vascular events after an initial recovery from COVID-19 form our impetus to investigate the impact of COVID-19 on vascular health of recovered patients. We found elevated levels of circulating endothelial cells (CECs), a biomarker of vascular injury, in COVID-19 convalescents compared to healthy controls. In particular, those with pre-existing conditions (e.g., hypertension, diabetes) had more pronounced endothelial activation hallmarks than non-COVID-19 patients with matched cardiovascular risk. Several proinflammatory and activated T lymphocyte-associated cytokines sustained from acute infection to recovery phase, which correlated positively with CEC measures, implicating cytokine-driven endothelial dysfunction. Notably, we found higher frequency of effector T cells in our COVID-19 convalescents compared to healthy controls. The activation markers detected on CECs mapped to counter receptors found primarily on cytotoxic CD8+ T cells, raising the possibility of cytotoxic effector cells targeting activated endothelial cells. Clinical trials in preventive therapy for post-COVID-19 vascular complications may be needed.

28 August 2020 in Circulation Research
Verified
Journal Article
Closed access
PDF file
WTWilson Lek Wen Tan
Wilson Lek Wen Tan
CAChukwuemeka George O. Anene-Nzelu
Chukwuemeka George O. Anene-Nzelu
EWEleanor Wong
Eleanor Wong
CLChang Jie Mick Lee
Chang Jie Mick Lee
HTHui San Tan
Hui San Tan
RTRewati Tappu
Rewati Tappu
Rationale: Identifying genetic markers for heterogeneous complex diseases such as heart failure is challenging and requires prohibitively large cohort sizes in genome-wide association studies to meet the stringent threshold of genome-wide statistical significance. On the other hand, chromatin quantitative trait loci, elucidated by direct epigenetic profiling of specific human tissues, may contribute toward prioritizing subthreshold variants for disease association. Objective: Here, we captured noncoding genetic variants by performing epigenetic profiling for enhancer H3K27ac chromatin immunoprecipitation followed by sequencing in 70 human control and end-stage failing hearts. Methods and Results: We have mapped a comprehensive catalog of 47 321 putative human heart enhancers and promoters. Three thousand eight hundred ninety-seven differential acetylation peaks (FDR [false discovery rate], 5%) pointed to pathways altered in heart failure. To identify cardiac histone acetylation quantitative trait loci (haQTLs), we regressed out confounding factors including heart failure disease status and used the G-SCI (Genotype-independent Signal Correlation and Imbalance) test 1 to call out 1680 haQTLs (FDR, 10%). RNA sequencing performed on the same heart samples proved a subset of haQTLs to have significant association also to gene expression (expression quantitative trait loci), either in cis (180) or through long-range interactions (81), identified by Hi-C (high-throughput chromatin conformation assay) and HiChIP (high-throughput protein centric chromatin) performed on a subset of hearts. Furthermore, a concordant relationship between the gain or disruption of TF (transcription factor)-binding motifs, inferred from alternative alleles at the haQTLs, implied a surprising direct association between these specific TF and local histone acetylation in human hearts. Finally, 62 unique loci were identified by colocalization of haQTLs with the subthreshold loci of heart-related genome-wide association studies datasets. Conclusions: Disease and phenotype association for 62 unique loci are now implicated. These loci may indeed mediate their effect through modification of enhancer H3K27 acetylation enrichment and their corresponding gene expression differences (bioRxiv: https://doi.org/10.1101/536763 ). Graphical A graphical abstract is available for this article.

29 November 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
NYNatalie Yeo
Natalie Yeo
ECEbenezer Jia Jun Chan
Ebenezer Jia Jun Chan
CCChristine Cheung
Christine Cheung
Many conditions affecting the heart, brain, and even the eyes have their origins in blood vessel pathology, underscoring the role of vascular regulation. In age-related macular degeneration (AMD), there is excessive growth of abnormal blood vessels in the eye (choroidal neovascularization), eventually leading to vision loss due to detachment of retinal pigmented epithelium. As the advanced stage of this disease involves loss of retinal pigmented epithelium, much less attention has been given to early vascular events such as endothelial dysfunction. Although current gold standard therapy using inhibitors of vascular endothelial growth factor (VEGF) have achieved initial successes, some drawbacks include the lack of long-term restoration of visual acuity, as well as a subset of the patients being refractory to existing treatment, alluding us and others to hypothesize upon VEGF-independent mechanisms. Against this backdrop, we present here a nonexhaustive review on the vascular underpinnings of AMD, implications with genetic and systemic factors, experimental models for studying choroidal neovascularization, and interestingly, on both endothelial-centric pathways and noncell autonomous mechanisms. We hope to shed light on future research directions in improving vascular function in ocular disorders.

27 March 2014 in Nature Protocols
Verified
Journal Article
Closed access
CCChristine Cheung
Christine Cheung
ABAndreia Sofia Bernardo
Andreia Sofia Bernardo
RPRoger A Pedersen
Roger A Pedersen
SSSanjay Sinha
Sanjay Sinha